Overview

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

BOOSTER is a randomised, controlled, phase II trial comparing osimertinib and bevacizumab versus osimertinib alone as second-line treatment in patients with stage IIIb-IVb non-small cell lung carcinoma (NSCLC) harbouring activating EGFR (exon 19 deletion or L858R) and T790M resistance mutation.

Phase:

Phase 2

Details

Lead Sponsor:

European Thoracic Oncology Platform

Collaborators:

AstraZeneca
Hoffmann-La Roche

Treatments:

Bevacizumab
Osimertinib